PCRX Pacira Corp: Long-Term Debt to Capital Coefficient

Pacira BioSciences (PCRX) revenues rely on a single primary analgesic drug, which drives the search for new injectable modifications to mitigate patent risks. Proprietary plants in the UK and US ensure sterile, automated product manufacturing. This chart illustrates that the asset's market value on GURU.Markets is 0.65, while it remains critical for the company to counter new forms of anesthetics that threaten its hospital contracts.

For Pacira BioSciences (PCRX), which is scaling the implementation of EXPAREL into US protocols, the ratio of long-term loans to equity reflects the balance between debt-funded expansion and the capital base. This indicator compares obligations with a maturity of over one year against shareholders' equity, where a downward trend may indicate either actual debt repayment or share dilution.